Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 158 publications
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.
Journal: Haematologica
Published: April 22, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.
Journal: Journal of hematology & oncology
Published: April 17, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
Journal: Blood cancer journal
Published: April 12, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 09, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.
Journal: American journal of hematology
Published: February 09, 2026
Global Epidemiologic Trends of Early-Onset Cancers From 1990 to 2021 and Projection to 2040.
Journal: JCO global oncology
Published: February 04, 2026
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Journal: Leukemia
Published: December 10, 2025
Optimizing Natural Killer Cellular Therapy in Acute Myeloid Leukemia.
Journal: American journal of clinical oncology
Published: December 03, 2025
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML.
Journal: American journal of hematology
Published: November 18, 2025
Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: October 31, 2025
Last Updated: 09/26/2026